Interferon-alpha for viral hepatitis

IFN-alpha has emerged as a promising treatment of chronic viral hepatitis. Although therapeutic response to IFN is far from universal, efficacy has been demonstrated; and studies combining IFN-alpha with other agents, as well as trials with new preparations of IFN-alpha, are under way. Children do not represent a large part of the identified population with chronic viral hepatitis. Yet children, by simple virtue of age, are more recently infected. In addition, longer life expectancies can be expected to be associated with greater morbidity from chronic viral hepatitis. Children seem to tolerate therapy with IFN-alpha well. Treatment of children with chronic viral hepatitis should be strongly considered, with protocols designed to ascertain specific pediatric safety and efficacy.

Author: Jonas MM, Combined Program in Gastroenterology, Children's Hospital, Boston, Massachusetts, USA. Source: J Pediatr Gastroenterol Nutr 23: 93-106 (1996)

Hepatitis C Genotype Guides Health Plans
Because the suggested treatment length and success rates vary between genotypes, this is typically one of the first distinctions made after a Hepatitis C diagnosis. In order to assure the correct course of therapy is approved, health insurance companies are...

Math May Foretell Hepatitis C Drug Success
By doing a math formula calculation on the specific genetics of an individual's Hepatitis C infection, doctors may be able to predict whether or not treatment will be successful....

Treatment Approved for Kids With Hepatitis C
Instead of prescribing the drugs for "off-label use," pediatricians can now feel more confident when treating children with Hepatitis C. Schering-Plough's Rebetol and PEG-Intron have been officially approved by the FDA for treating Hepatitis C in kids aged 3 to...